Gene Therapy Treats Bovine Maple Syrup Urine Disease

Researchers successfully used gene therapy on a calf to address a rare metabolic condition.

Updated on Oct. 27, 2026 in Biotech

A healthy, full-grown heifer grazes in a wide, dew-covered green pasture during a clear, golden-lit morning. — Researchers in Lancaster successfully treated a calf for maple syrup urine disease using viral gene therapy, with the animal remaining healthy years later. AI Illustration. Upload story photo >

In 2021, researchers in Lancaster successfully treated a 79-pound calf named Petunia for maple syrup urine disease using viral gene therapy. The heifer, now 5 years old, continues to thrive at a current weight of 1,500 pounds.

Why it matters

This breakthrough study aims to prove that gene therapy could eventually serve as a viable treatment for humans suffering from the same metabolic disorder. The project represents the culmination of two decades of research by Kevin Strauss to find an effective intervention.

The heifer Petunia currently weighs 1,500 pounds, a significant increase from her 79-pound weight when she underwent treatment. The therapeutic approach was developed over the course of two decades.

The players

Petunia

A 5-year-old heifer who served as the subject of a successful gene therapy trial for maple syrup urine disease.

Kevin Strauss

A researcher who has dedicated two decades to developing a treatment for maple syrup urine disease.

The details

Researchers injected a virus carrying corrective genes into the calf at a veterinary hospital after monitoring her for two nights to stabilize her condition. While the treatment successfully addressed the metabolic disease in the animal, no human patients have yet received this specific therapy.

The calf was treated with gene therapy in 2021.
This report was published on October 27, 2026.

The Big Picture

This study marks a milestone in maple syrup urine disease research programs by providing proof of concept for gene therapy in a large animal model. The experiment serves to validate the broader theoretical potential of gene editing to correct metabolic disorders.

This development offers a potential future treatment path for patients currently managing maple syrup urine disease through strict dietary restrictions. The research highlights how gene therapies could eventually replace lifelong medical management for inherited metabolic conditions.

The takeaway

The successful treatment of Petunia provides a vital stepping stone toward human applications for this rare condition. Ongoing research remains essential to bridge the gap between successful animal models and clinical safety for human patients.